---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-108804"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:29:44.276125+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones

## Summary
- Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.
- Lilly gets exclusive worldwide rights to AAV-AIPL1 for LCA4, which restored vision in 11 blind children.
- Also licenses proprietary intravitreal capsids, promoters (AI-generated), and riboswitch gene-editing rights.
- MeiraGTx eligible for tiered royalties; retains ownership of certain technology improvements; Lilly funds all R&D and commercialization.

## SEC filing metadata
- accession: 0001104659-25-108804
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000110465925108804/0001104659-25-108804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000110465925108804/mgtx-20251107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-108804
- JSON: https://secwatch.observer/filing/0001104659-25-108804.json
- Plain text: https://secwatch.observer/filing/0001104659-25-108804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.